Patents by Inventor Howard Levin

Howard Levin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200009357
    Abstract: A method and apparatus for treatment of heart failure by increasing secretion of endogenous naturetic hormones ANP and BNP such as by stimulation of the heart atria. Heart pacing is done at an atrial contraction rate that is increased and can be higher than the ventricular contraction rate. Pacing may include mechanical distension of the right atrial appendage. An implantable device is used to periodically cyclically stretch the walls of the appendage with an implanted balloon.
    Type: Application
    Filed: June 26, 2019
    Publication date: January 9, 2020
    Inventors: Howard Levin, Mark Gelfand
  • Publication number: 20190350650
    Abstract: A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.
    Type: Application
    Filed: July 12, 2019
    Publication date: November 21, 2019
    Applicant: Axon Therapies, Inc.
    Inventors: Howard LEVIN, Mark GELFAND
  • Publication number: 20190275336
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 12, 2019
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 10376308
    Abstract: A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 13, 2019
    Assignee: Axon Therapies, Inc.
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 10369333
    Abstract: A method and apparatus for treatment of heart failure by increasing secretion of endogenous naturetic hormones ANP and BNP such as by stimulation of the heart atria. Heart pacing is done at an atrial contraction rate that is increased and can be higher than the ventricular contraction rate. Pacing may include mechanical distension of the right atrial appendage. An implantable device is used to periodically cyclically stretch the walls of the appendage with an implanted balloon.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: August 6, 2019
    Assignee: BackBeat Medical, Inc.
    Inventors: Howard Levin, Mark Gelfand
  • Publication number: 20190183569
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Application
    Filed: December 17, 2018
    Publication date: June 20, 2019
    Inventors: Dorin PANESCU, Andrew WU, Zoar Jacob ENGELMAN, Mark GELFAND, Mark S. LEUNG, Howard LEVIN
  • Publication number: 20190175912
    Abstract: Disclosed herein is a device, and method for treating heart failure by electrically modulating a splanchnic nerve with an implantable device.
    Type: Application
    Filed: February 15, 2019
    Publication date: June 13, 2019
    Inventors: Mark GELFAND, Tamara Colette BAYNHAM, Howard LEVIN
  • Patent number: 10252060
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: April 9, 2019
    Assignee: BackBeat Medical, Inc.
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 10219855
    Abstract: Systems, devices, and methods for treating a patient having a sympathetically mediated disease associated at least in part with augmented peripheral chemoreflex or heightened sympathetic activation. The treatments include ablating one or more peripheral chemoreceptors or associated afferent nerves to reduce or remove afferent neural signals from the peripheral chemoreceptor.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: March 5, 2019
    Assignee: Cibiem, Inc.
    Inventors: Mark Gelfand, Howard Levin
  • Publication number: 20190060538
    Abstract: Devices to improve lung function in a patient having restricted ventilation. The device may include an entry or access port for an implantable airway bypass device that relieves trapped air. The device of the present invention comprises an expandable structure (164) to be implanted in lung tissue and defining an air capture chamber, a first conduit (174) having a first end from which extends the expandable structure, and a second end to be coupled to a first end of a second conduit (161), the second end of the second conduit being joined to an external anchor (175) to rest against an outer skin surface of the chest of the patient.
    Type: Application
    Filed: October 31, 2016
    Publication date: February 28, 2019
    Inventors: Mark GELFAND, Jianmin LI, George BOURNE, Howard LEVIN, Benjamin David BELL, Gerhard A. FOELSCHE, Aaron SANDOSKI
  • Patent number: 10207110
    Abstract: Disclosed herein is a device, and method for treating heart failure by electrically modulating a splanchnic nerve with an implantable device.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: February 19, 2019
    Assignee: Axon Therapies, Inc.
    Inventors: Mark Gelfand, Tamara Colette Baynham, Howard Levin
  • Publication number: 20190046723
    Abstract: A fluid therapy method for an ADHF patient includes setting a urine output rate desired threshold, setting one or more desired negative net gain rates, and optionally setting a total fluid loss goal. The urine output of the patient is monitored and fluid is automatically administered to the patient at increasing rates to equal to or approximately match the patient's increasing urine output rates until the patient's urine output rate reaches the set urine output rate desired threshold. Thereafter, fluid is administered to the patient at rates to achieve the set desired negative net gain rate until the fluid loss goal is reached. Thereafter, until the end of therapy, fluid is administered to the patient at rates equal to or approximately equal to the monitored urine output rates.
    Type: Application
    Filed: October 5, 2018
    Publication date: February 14, 2019
    Inventors: Andrew HALPERT, Mark TAUSCHER, Mark GELFAND, Howard LEVIN
  • Patent number: 10194983
    Abstract: Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: February 5, 2019
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Neil Barman, Howard Levin, Paul Sobotka, Mark Gelfand
  • Publication number: 20180326151
    Abstract: A fluid therapy method for an ADHF patient includes setting a urine output rate desired threshold, setting one or more desired negative net gain rates, and optionally setting a total fluid loss goal. The urine output of the patient is monitored and fluid is automatically administered to the patient at increasing rates to equal to or approximately match the patient's increasing urine output rates until the patient's urine output rate reaches the set urine output rate desired threshold. Thereafter, fluid is administered to the patient at rates to achieve the set desired negative net gain rate until the fluid loss goal is reached. Thereafter, until the end of therapy, fluid is administered to the patient at rates equal to or approximately equal to the monitored urine output rates.
    Type: Application
    Filed: July 11, 2018
    Publication date: November 15, 2018
    Inventors: Andrew V. HALPERT, Mark TAUSCHER, Mark GELFAND, Howard LEVIN
  • Publication number: 20180326209
    Abstract: Detection and treatment of disordered breathing is disclosed, with treatment being primarily delivered using electrical stimulation of the diaphragm, either directly or by stimulating appropriate nerves.
    Type: Application
    Filed: May 21, 2018
    Publication date: November 15, 2018
    Inventors: Mark Gelfand, Howard Levin, Andrew Halpert, Antonis Panteleon
  • Publication number: 20180185577
    Abstract: A fluid therapy method for an ADHF patient includes setting a urine output rate desired threshold, setting one or more desired negative net gain rates, and optionally setting a total fluid loss goal. The urine output of the patient is monitored and fluid is automatically administered to the patient at increasing rates to equal to or approximately match the patient's increasing urine output rates until the patient's urine output rate reaches the set urine output rate desired threshold. Thereafter, fluid is administered to the patient at rates to achieve the set desired negative net gain rate until the fluid loss goal is reached. Thereafter, until the end of therapy, fluid is administered to the patient at rates equal to or approximately equal to the monitored urine output rates.
    Type: Application
    Filed: March 12, 2015
    Publication date: July 5, 2018
    Inventors: Andrew V. Halpert, Mark Tauscher, MARK GELFAND, HOWARD LEVIN
  • Publication number: 20180168723
    Abstract: Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states.
    Type: Application
    Filed: December 11, 2017
    Publication date: June 21, 2018
    Inventors: Neil Barman, Howard Levin, Paul Sobotka, Mark Gelfand
  • Patent number: 9987488
    Abstract: Detection and treatment of disordered breathing, with treatment being primarily delivered using electrical stimulation of the diaphragm, either directly or by stimulating appropriate nerves. In some embodiments, the stimulus is applied to still at least one lung upon detection of an apnea-hypopnea of some length or upon the detection of hyperpnea. The stimulation may be initiated during the apnea-hypopnea period or upon detection of a breath of a predetermined intensity near the end of apnea-hypopnea. The stimulation may be initiated in phase with respiration or irrespective of the phase of respiration.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: June 5, 2018
    Assignee: Respicardia, Inc.
    Inventors: Mark Gelfand, Howard Levin, Andrew Halpert, Antonis Panteleon
  • Publication number: 20180110561
    Abstract: A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.
    Type: Application
    Filed: February 5, 2016
    Publication date: April 26, 2018
    Inventors: Howard LEVIN, Mark GELFAND
  • Publication number: 20180071455
    Abstract: A fluid therapy method for an ADHF patient includes setting a urine output rate desired threshold, setting one or more desired negative net gain rates, and optionally setting a total fluid loss goal. The urine output of the patient is monitored and fluid is automatically administered to the patient at increasing rates to equal to or approximately match the patient's increasing urine output rates until the patient's urine output rate reaches the set urine output rate desired threshold. Thereafter, fluid is administered to the patient at rates to achieve the set desired negative net gain rate until the fluid loss goal is reached. Thereafter, until the end of therapy, fluid is administered to the patient at rates equal to or approximately equal to the monitored urine output rates.
    Type: Application
    Filed: March 12, 2015
    Publication date: March 15, 2018
    Inventors: Andrew V. Halpert, Mark Tauscher, MARK GELFAND, HOWARD LEVIN